Skip to main content

Denali Therapeutics Inc

For the period ended Dec 31, 2023. Filed Feb 28, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 28, 2024

DNLI$20.33+1.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

DENALI THERAPEUTICS INC.
Date:February 27, 2024By:/s/ Ryan J. Watts
Ryan J. Watts, Ph.D.
President and Chief Executive Officer

POWER OF ATTORNEY

Each person whose signature appears below constitutes and appoints Ryan J. Watts, Ph.D. and Alexander O. Schuth, M.D., and each of them acting individually, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes, may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated:

SignatureTitleDate
/s/ Ryan J. WattsPresident, Chief Executive Officer and Director(Principal Executive Officer)February 27, 2024
Ryan J. Watts, Ph.D.
/s/ Alexander O. SchuthChief Operating and Financial Officer(Principal Financial and Accounting Officer)February 27, 2024
Alexander O. Schuth, M.D.
/s/ Vicki SatoChairperson of our Board of DirectorsFebruary 27, 2024
Vicki Sato, Ph.D.
/s/ Jennifer CookDirectorFebruary 27, 2024
Jennifer Cook
/s/ Jay FlatleyDirectorFebruary 27, 2024
Jay Flatley
/s/ Erik HarrisDirectorFebruary 27, 2024
Erik Harris
/s/ Peter KleinDirectorFebruary 27, 2024
Peter Klein
/s/ Steve E. KrognesDirectorFebruary 27, 2024
Steve E. Krognes
/s/ David SchenkeinDirectorFebruary 27, 2024
David Schenkein, M.D.
/s/ Marc Tessier-LavigneDirectorFebruary 27, 2024
Marc Tessier-Lavigne, Ph.D.
/s/ Nancy A. ThornberryDirectorFebruary 27, 2024
Nancy A. Thornberry
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.